LGVN · Longeveron Inc. · Investor Relations

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxiv MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences. 13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation) Longevity Partnering Forum to be held October 19-20, 2026 in South San Francisco Longevity and Aging-Related Frailty The Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty. Results from a Phase 2b clinical trial demonstrated that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. These results were published in Cell Stem Cell in February 2026. Further, based on these clinical trial results, Longeveron announced in August 2026 that it was selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron received the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million. New Analysis of Laromestrocel Phase 2a Data in Alzheimer’s Disease Published on medRxiv The Company has recently published a new manuscript as a pre-print in medRxiv, detailing post-hoc exploratory analysis from the Company’s Phase 2a randomized CLEAR MIND study (NCT05233774; n=49) in AD that indicated laromestrocel treatment may reduce neuroinflammation in the brain—a core driver of AD pathogenesis, using free water MRI imaging. This is a preprint and has not yet completed peer review. Laromestrocel is an investigational product and has not been approved by the FDA or any other regulatory agency. Read the full preprint: https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1 Key findings: Laromestrocel inhibited the progression of neuroinflammation, with the strongest effects in regions at the core of Alzheimer's pathology, including the left hippocampus (p Reduced neuroinflammation correlated with less brain atrophy and with improved clinical scores, particularly cognition as measured by MoCA. Treated participants showed lower plasma neurogranin, consistent with reduced synaptic loss. Blood biomarker analyses point to a convergent, multimodal mechanism of action involving peripheral immune engagement. Together, these results support the hypothesis that laromestrocel's potential anti-inflammatory effects may help protect brain tissue and function in Alzheimer's disease. If confirmed, durable anti-inflammatory effects may also be useful in combatting chronic inflammation in aging, or “inflammaging”. These new results follow publication of main CLEAR MIND trial results in Nature Medicine in 2025. https://www.nature.com/articles/s41591-025-03559-0 About laromestrocel (Lomecel-B ® ) Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young, healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to the human endogenous biological repair mechanism. MSCs have the potential to perform a number of complex functions in the body and possibly support tissue repair and regenerative signaling pathways. They also may respond to sites of injury or disease and may secrete bioactive factors that are immunomodulatory and regenerative. We believe laromestroc

Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy in clinical studies across multiple indications and has received 5 designations from FDA Laromestrocel has shown positive initial results in Aging-related Frailty, including publication of clinical trial results in Cell Stem Cell and selection as a Finalist awardee in the XPRIZE Healthspan global competition The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value MIAMI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12. In the intent-to-treat (ITT) population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336). Initial exploratory clinical outcomes in the as-treated analyses include: Over a 12-month period, there were no deaths in patients that received laromestrocel, compared to one patient in the control group, in the as-treated group Over a long-term follow up of transplant-free survival (up to five years across all patients), the laromestrocel arm had one event (out of 17 patients) vs. two events (out of 21 patients) in the standard-of-care arm Hospitalization burden was similar between arms Adjudicated Major Adverse Cardiovascular Events (MACE) were approximately 31% fewer in the laromestrocel arm (12 events in the treated arm vs. 19 events in the untreated arm, respectively). However, the negative binomial analysis was not statistically significant. A sponsor-defined exploratory hierarchical composite endpoint consisting of all-cause mortality and duration of inpatient hospitalization was not statistically significant in the ITT population. Laromestrocel demonstrated a safety profile generally consistent with prior clinical trials, and no new safety signals were identified in the study. The Company is conducting additional analyses of the complete dataset and intends to discuss the results with the U.S. Food and Drug Administration (FDA) to determine potential next steps for the HLHS development program. FDA previously indicated its willingness to meet with the Company following completion of the study to discuss the results and potential paths forward. Sunjay Kaushal, M.D., Ph.D., Professor of Surgery, Cardiovascular and Thoracic Surgery at University of Nevada, Las Vegas commented: “There remains a significant unmet medical need to boost the survival of the babies undergoing standard of care surgeries that still have only a 50-60% survival rate to adolescence with approximately 20% requiring heart transplant. ELPIS II provides evidence of the safety of using stem cells to address this unmet need.” Laromestrocel demonstrated a favorable safety and tolerability profile in ELPIS II, consistent with the safety experience observed across Longeveron’s clinical development programs, in which 644 par

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28 th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date: Monday, September 14, 2026 Time: 1:00 – 1:30 p.m. ET The webcast for this conference presentation may be accessed at the “ Events and Presentations ” section of the Company’s website. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B ® ), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn , X , and Instagram . Investor and Media Contact: Derek Cole Investor Relations Advisory Solutions [email protected] Source: Longeveron

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board of Directors on July 31, 2026. The 2026 Reverse Split is expected to become effective at 11:59 p.m. Eastern Time, on August 26, 2026, and the Company’s Class A common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on August 27, 2026 under a new CUSIP number 54303L 302 and the existing ticker symbol “LGVN.” The 2026 Reverse Split is intended to increase the per share trading price of the Company’s Class A common stock to enable the Company to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Capital Market. “Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business and we believe our share structure should better align with the opportunities we see ahead,” said Stephen Willard, Chief Executive Officer at Longeveron. “This reverse split is a structural adjustment. It does not change our capital efficient strategy, our operations, or the value of any stockholder’s position apart from adjustments for fractional shares. In addition to supporting our compliance with Nasdaq’s continued listing requirements, we believe the 2026 Reverse Split more appropriately aligns our stock with institutional investor preferences, potentially enabling a broader ownership base.” The 2026 Reverse Split will automatically convert every ten current shares of the Company’s Common Stock, whether issued and outstanding or held by the Company as treasury stock, into one share of fully paid and nonassessable Common Stock. No fractional shares will be issued in connection with the 2026 Reverse Split. In lieu thereof, any fractional shares resulting from the 2026 Reverse Split will be rounded up to the nearest whole share at the Depository Trust Company (“DTC”) participant level. The Company will not round up fractional shares at the beneficial ownership level. No cash consideration will be paid to stockholders in connection with the 2026 Reverse Split. The 2026 Reverse Split will reduce the aggregate number of shares of outstanding Class A common stock from approximately 30,432,974 shares to approximately 3,043,298 shares, and the number of shares of outstanding Class B common stock from approximately 1,449,005 shares to approximately 144,901 shares (based on outstanding shares as of August 6, 2026). The total authorized number of shares and par value of shares will remain unchanged. The terms of all outstanding warrants currently exercisable for shares of Class A common stock, and all equity awards granted under the Company’s equity plans, including the per share exercise price of options and the number of shares issuable under such options, will be proportionally adjusted to maintain their economic value, subject to adjustments for any fractional shares as described above. In addition, the total number of shares of Common Stock that may be the subject of future grants under the Company’s equity plans, as well as any plan limits on the size of such grants will be adjusted and proportionally decreased as a result of the 2026 Reverse Split. Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-2026 Reverse Split shares.

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the prior CFO. Ms. Washburn will return to her former role as the Company’s Corporate Controller. “I am delighted to welcome Nirav as Longeveron’s Chief Financial Officer,” said Steven H. Willard , Chief Executive Officer of Longeveron. “His significant experience in biotech company corporate finance and capital markets will be a tremendous asset as Longeveron continues to advance the development of our stem cell therapy across four indications, each addressing a significant unmet medical need. Our Phase 2b clinical trial evaluating laromestrocel as a potential treatment for HLHS, a devastating rare pediatric and orphan designated indication, is anticipated to produce top-line trial results in September of this year.” Mr. Jhaveri commented, “I am incredibly excited to join the Company at this potentially transformational period in its history. With strong initial data across multiple indications, I believe Longeveron is well positioned to be a leader in advancing the adoption of stem cell therapy in healthcare. I look forward to working closely with Steve, the Board of Directors and the entire Longeveron team to ensure the long-term success of laromestrocel while enhancing the Company’s operational functions.” Mr. Jhaveri has served as Chief Financial Officer at public and venture-backed biotech companies, with over 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector, and a track record across capital raising, licensing and M&A transactions, and IPO readiness. Before joining Longeveron, Mr. Jhaveri served as CFO of Opus Genetics (Nasdaq: IRD), a gene therapy company focused on inherited retinal diseases; Insilico Medicine (HKEX: 3696.HK), an AI-driven drug discovery company; and Journey Medical Corporation (Nasdaq: DERM), a commercial-stage dermatology company. Earlier in his career, Mr. Jhaveri held roles in business development at Fortress Biotech, equity research at Citigroup, and investment banking at Bank of America. He is a CFA (Chartered Financial Advisor) charterholder. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B ® ), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn , X , and Instagram . Forward-Looking Stat

On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty Three new independent Directors join Longeveron’s Board of Directors Company to host conference call and webcast today at 4:30 p.m. ET MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2026 and provided a business update. “Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business,” said Stephen H. Willard , Chief Executive Officer of Longeveron. “Our approach to stem cell therapy development has garnered external recognition and validation with positive clinical data having been published in Nature Medicine and Cell Stem Cell and also serving as the foundation for our selection as a Finalist for the XPRIZE Healthspan competition out of over 600 projects submitted worldwide. We are rapidly approaching the September top line data readout of our ELPIS II Phase 2b clinical trial evaluating laromestrocel in HLHS and look forward to sharing those results.” Development Programs Longeveron’s investigational therapeutic candidate laromestrocel (Lomecel-B ®) is a proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications. Hypoplastic Left Heart Syndrome (HLHS) – a rare pediatric congenital heart birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. Topline results from the Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct therapy for HLHS are anticipated in September 2026. In May, the Company announced that the U.S. Food and Drug Administration (FDA) held a Type C meeting in late March 2026 focused on the ELPIS II Phase 2b clinical trial and upcoming data readout. Also in May, the Company announced that the independent Data Monitoring Committee (DMC) completed its final prespecified data review for ELPIS II Phase 2b clinical trial (ELPIS II). The DMC performed a risk-benefit assessment, indicated no safety concerns, and approved the study to continue as designed to completion. ELPIS II is being conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through grants from the National Institutes of Health (NIH) . The FDA has granted laromestrocel Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the treatment of HLHS. Pediatric Dilated Cardiomyopathy (PDCM) – a rare pediatric cardiovascular disease in which the muscles in one or more of the heart chambers become enlarged or stretched (dilated), with nearly 40% of children with PDCM requiring a heart transplant or dying within two years of diagnosis. Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for PDCM became effective in July 2025. This IND provides for moving directly to a single Phase 2 registrational clinical trial. The Company currently anticipates initiation of the Phase 2 clinical trial in 2027, with planning and preparation beginning in 2026. Alzheimer’s disease (AD) – a neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options. In July, additional analysis of data from the Phase 2a clinical trial eval

Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron will receive the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million. XPRIZE Healthspan is a 7-year global competition incentivizing teams to develop and test therapeutics that restore muscle, cognition, and immune function in adults aged 50 to 90 by a minimum of 10 years, with an ambitious goal of 20 years, to extend healthy life within one year or less of treatment. “We are extremely proud and enthusiastic to participate as a Milestone 2 Awardee of XPRIZE Healthspan, a 7-year, $101 million global competition that aims to revolutionize the way we approach human aging,” said Stephen H. Willard , Chief Executive Officer of Longeveron. “We look forward to the next chapter of the competition as we continue to develop our stem cell therapy that we believe has the potential to have a significant impact for patients and their families, and extend healthy life.” “Our stem cell therapy laromestrocel is an allogeneic mesenchymal stem cell supported by a robust intellectual property portfolio of 52 issued patents worldwide. Its potential mechanisms of action comprising anti-inflammatory, pro-vascular, and pro-regenerative effects support its potential application across multiple important indications with high unmet medical need,” commented Dr. Joshua Hare , Co-Founder, Chief Science Officer and Executive Chairman of Longeveron. “Laromestorcel has delivered several positive initial results across 5 clinical trials in 3 indications - Alzheimer’s Disease , Aging-related Frailty , and Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric and orphan-designated disease. Based on positive initial data, laromestrocel development programs have received five U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the Alzheimer’s Disease program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. We continue to advance a “pipeline-in-a-product” strategy, with multiple indications that can be independently developed, partnered, or licensed, creating multiple potential pathways for value creation.” XPRIZE team applications were rigorously evaluated for scientific merit and clinical readiness to identify the best, most feasible, and safe approaches to increase human healthspan. The Milestone 2 Awardees, out of more than 600 applicants across 58 countries, were selected as Finalist Awardees. The XPRIZE criteria was that the Finalist Awardees must present a single or combination therapeutic approach that demonstrates feasibility and potential to restore or preserve muscular, cognitive, and immune function lost to age-related degradation by at least 10 years, with an ambitious goal of 20 years, and deliver their therapy in 1-year or less in adults aged 50-90 years who are free of major or life-threatening disease and disability. The Top 10 Milestone 2 Award-winning teams are each receiving $1,000,000 to advance their therapeutic approach into the final phase of the competition, where teams will conduct coordinated clinical trials through 2029. The grand prize will award up to $81 million to the winning team. About XPRIZE XPRIZE is the recognized global leader in designing and ex

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number: 1.877.407.0789 Conference ID: 13761959 Call me™ Feature: Click Here Webcast: Click Here An archived replay of the webcast will be available on the “ Events & Presentations ” section of the Company’s website following the conference. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn , X , and Instagram . Investor and Media Contact: Derek Cole Investor Relations Advisory Solutions [email protected] Source: Longeveron

Dr. Ascheim has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development track record with gene, cell and biologics, to the Board of Directors,” said Dr. Joshua M. Hare, Executive Chairman and Chief Science Officer of Longeveron. “I look forward to working with her as we continue to advance our stem cell therapy laromestorcel. Our HLHS program represents our most advanced and near-term value catalyst. HLHS is a rare and life-threatening pediatric congenital heart condition with no approved drug therapies and significant mortality despite surgical intervention.” Dr. Ascheim commented, “I am delighted to join the Board of Directors of Longeveron at this exciting juncture in the Company’s stem cell clinical development history. Laromestrocel’s potential mechanisms of action—including anti-inflammatory, pro-vascular, and pro-regenerative effects—support its potential as a platform product with potential therapeutic applications across multiple high-value indications with profound unmet medical need.” Dr. Ascheim currently serves as the Fractional Chief Medical Officer at Rejuvenate Bio, Inc., a clinical stage biotech company developing gene therapies to treat age-related diseases in humans and dogs. She is the founder and president of d2a Ltd. where she currently works as an independent consultant providing strategic leadership, clinical and product development across a wide range of therapeutic areas and technologies, including gene and cell therapies, small molecules, pharmaceuticals, and diagnostic and therapeutic devices. Dr. Ascheim also serves on the Advisory Board of the Mass General Brigham Gene and Cell Therapy Institute. Before she joined Rejuvenate Bio, Inc. in 2023, Dr. Ascheim served as the Chief Medical Officer for StrideBio, Inc., a fully integrated patient-centric gene therapy company focused on creating and developing innovative genetic medicines for patients with devastating conditions. From 2020 to 2021, Dr. Ascheim worked as an independent consultant providing clinical development guidance for developing advanced generation gene therapies for rare diseases. Dr. Ascheim previously served as the Chief Medical Officer for Capricor Therapeutics Inc., a NASDAQ-listed company, where she, among other things, led clinical development strategy and execution, initiated and completed enrollment in Phase I/II DMD clinical trials, and was responsible for medical monitoring of all clinical trials. Dr. Ascheim’s clinical career was focused on heart failure cardiology. She was a member of the Heart Failure Center, Division of Circulatory Physiology faculty at Columbia Presbyterian Medical Center. During her academic tenure, Dr. Ascheim had over two decades of experience as a clinical researcher and trialist, serving either as the Principal Investigator or other leadership role on grant funded NIH and industry trials totaling more than $140 million. Dr. Ascheim served on the Board of Directors for Physicians for Human Rights from 2008 to 2023 and during her time served many roles including as the Chair to the Board of Directors and the Chair of the Nominating & Governance and Compensation Committees. Dr. Ascheim earned her B.A. from Wellesley College and her M.D. from NYU Grossman School of Medicine. About Longeveron Inc.

Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI ” presented at July 13 th In Person Poster Presentation Session Results support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimer’s disease Longeveron has received U.S. FDA RMAT designation for its Alzheimer’s disease program and has aligned on a Phase 3 study design MIAMI, July 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer’s disease (AD) is being presented in a Poster Presentation at the 2026 Alzheimer’s Association International Conference ® (AAIC ® ) , being held July 12-15, 2026 in London, United Kingdom and online. Results presented in “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI ” provide support for a clinically relevant and durable anti-inflammatory mechanism of action of laromestrocel in gray and white matter and indicate potential blood biomarker correlates. Importantly, the reduction on free water detected by MRI correlates with both improved clinical outcomes and the anti-atrophic responses in the brain. A key contributor to AD brain atrophy and clinical pathology is progressive neuroinflammation, and no therapeutic to date has been successful in mitigating the destructive inflammation of AD. Brain inflammation can be indexed using free water MRI. Longeveron previously found that free water rose substantially during AD pathogenesis in the brains of individuals in the placebo group, particularly in the hippocampus, temporal lobe, and other key AD regions, but subjects treated with laromestrocel showed no increase. Together with previously published data, these results showed that laromestrocel, a human bone marrow-derived, mesenchymal stem cell therapy with anti-inflammatory and pro-vascular effects, substantially reduced brain atrophy and lowered free water in a proof of concept, randomized Phase 2a trial (CLEAR-MIND). In this new post-hoc exploratory analysis of CLEAR-MIND results, the anti-inflammatory effect was observed to be most prominent in the hippocampus, temporal lobe, and other AD-associated areas and correlated (Spearman) with both increased brain volume and improved cognitive and quality of life scores. Laromestrocel infusion groups were: 1) placebo, 2) 25 million cells, single dose (25Mx1), 3) 25M cells over 4 monthly doses (25Mx4) or 4) 100M cells over 4 monthly doses (100Mx4), vs placebo. Data were statistically modeled using Mixed Model Repeated Measures (MMRM). In the placebo population (N=10), free water rose over 39 weeks in key white matter regions: the fornix, sagittal stratum, uncinate fasciculus. However, free water was numerically reduced compared with placebo in all groups receiving laromestrocel (fornix at week 26: 25Mx4, N=11, p=0.058; sagittal stratum at week 39: pooled 25Mx4 and 100Mx4 treatment groups, N=21, p=0.063; uncinate fasciculus (left) at week 39: 100Mx4, N=10, p=0.064). This reduction trend in free water correlated (Spearman) with Longeveron’s recent findings showing significantly reduced free water compared with placebo at 39 weeks in key gray matter regions: hippocampus, the temporal, parietal, and occipital lobes, and medulla, and with improvements in clinical scores. Blood plasma samples from the trial were assessed using NuLISA. Pla

Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 MIAMI, July 06, 2026 (GLOBE NEWSWIRE) - Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company’s executive leadership team in the role of Senior Vice President and Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer, effective July 13, 2026. She succeeds Lisa Locklear who, as previously announced, is stepping down to pursue board opportunities and other professional and personal interests. “Marie has had a tremendously positive impact on the Company

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer’s disease has been accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference® (AAIC®) , to be held July 12-15, 2026 in London, United Kingdom and online. Poster Presentation (Exhibit Hall) Date: Monday, July 13, 2026 Time: 7:30am – 4:15pm BST Session: In-Person Posters Tuesday; Drug Development: Human Topic: Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer’s disease and provided evidence-based support for